Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid

Gravani, Agoritsa; Christou, Panagiota A.; Tigas, Stelios; Bassukas, Ioannis D.

doi:10.1016/j.abd.2020.10.010

Cited by 1 publication

(1 citation statement)

References 4 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, gliptins and sulphur-containing drugs may have an additive effect on BP induction ( 13 ). In a recent case-control study by Gravani et al ( 29 ), anticoagulants, proton pump inhibitors, and selective serotonin reuptake inhibitors were associated with a significantly higher risk of drug-associated BP. In light of these results, we suggest that patients’ prescribed medications should be thoroughly reviewed.…”

Section: Discussionmentioning

confidence: 94%

Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients

Shalmon,

Bar-Ilan,

Peled

et al. 2024

Acta Derm Venereol

View full text Add to dashboard Cite

Drug-associated bullous pemphigoid has been shown to follow long-term gliptin (dipeptidyl-peptidase 4 inhibitors) intake. This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes. A retrospective study was conducted in a tertiary centre among diabetic patients exposed to gliptins between the years 2008–2021. Data including demographics, comorbidities, medications, and laboratory results were collected using the MDClone platform. Seventy-six patients with type 2 diabetes treated with dipeptidyl-peptidase 4 inhibitors who subsequently developed bullous pemphigoid were compared with a cohort of 8,060 diabetic patients exposed to dipeptidyl-peptidase 4 inhibitors who did not develop bullous pemphigoid. Based on a multivariable analysis adjusted for age and other covariates, Alzheimer’s disease and other dementias were significantly more prevalent in patients with bullous pemphigoid (p = 0.0013). Concomitant use of either thiazide or loop diuretics and gliptin therapy was associated with drug-associated bullous pemphigoid (p < 0.0001 for both). While compared with sitagliptin, exposure to linagliptin and vildagliptin were associated with bullous pemphigoid with an odds ratio of 5.68 and 6.61 (p < 0.0001 for both), respectively. These results suggest gliptins should be prescribed with caution to patients with type 2 diabetes with coexisting Alzheimer’s and other dementias, or patients receiving long-term use of thiazides and loop diuretics. The use of sitagliptin over linagliptin and vildagliptin should be preferred in these patients.

show abstract

Section: Discussionmentioning

confidence: 94%